DREAM3R Phase 3 Trial Shows Promise but Inconclusive Results for Durvalumab in Advanced Pleural Mesothelioma
核心洞察
The phase 3 DREAM3R trial demonstrated favorable trends for durvalumab plus chemotherapy in advanced pleural mesothelioma (搜索), with median overall survival of 21 months versus 18 months for chemotherapy alone.
Despite showing a 58% objective response rate compared to 35% with chemotherapy alone, slow patient accrual and evolving standard-of-care practices led to early trial termination and inconclusive results.
The study's design was complicated by the 2021 CheckMate 743 results establishing nivolumab plus ipilimumab as the new standard of care, making chemotherapy alone no longer appropriate as a control arm.
The phase 3 DREAM3R trial of durvalumab (Imfinzi) plus chemotherapy in advanced pleural mesothelioma (搜索) has yielded promising but ultimately inconclusive results, highlighting the challenges of conducting clinical trials in rapidly evolving treatment landscapes. Data presented at the 2025 European Society for Medical Oncology (ESMO) Congress showed favorable survival trends but fell short of providing definitive answers due to early trial termination.
Clinical Outcomes Show Positive Trends
In the DREAM3R study (NCT04334759), 114 patients receiving durvalumab plus chemotherapy achieved a median overall survival of 21 months (95% CI, 18–27) compared to 18 months (95% CI, 14–30) for 60 patients receiving chemotherapy alone, yielding a hazard ratio of 0.92 (95% CI, 0.63–1.36; stratified log-rank P = 0.9).
Progression-free survival showed similar trends, with the combination therapy achieving 8 months (95% CI, 8–10) versus 7 months (95% CI, 6–8) for chemotherapy alone (HR, 0.70; 95% CI, 0.5–0.98; P = 0.20). The most striking difference emerged in objective response rates, where durvalumab plus chemotherapy achieved 58% compared to 35% with chemotherapy alone (P = 0.005).
The safety profile remained consistent with known effects of the individual agents, with fatigue, nausea, and anemia representing the most common adverse events in both treatment arms.
Trial Design Challenges and Modifications
The DREAM3R trial began patient accrual in February 2021, initially randomizing patients 2:1 to receive durvalumab 1500 mg every 3 weeks plus chemotherapy for 4 to 6 cycles, followed by durvalumab maintenance 1500 mg every 4 weeks until disease progression, versus chemotherapy alone for 4 to 6 cycles.
However, the trial faced significant disruption when the CheckMate 743 study results were published in 2021, demonstrating that nivolumab (Opdivo) plus ipilimumab (Yervoy) significantly improved overall survival compared to chemotherapy in pleural mesothelioma (搜索). This development fundamentally altered the standard of care, forcing investigators to modify the study design to incorporate a nivolumab/ipilimumab arm and change randomization to 1:1 between durvalumab/chemotherapy and physician's choice of nivolumab/ipilimumab or chemotherapy.
Study Limitations and Early Termination
Anna Nowak, MD, deputy vice chancellor at the University of Western Australia and the study's lead investigator, acknowledged that while DREAM3R was well-designed, early stopping due to slow accrual makes it unlikely that the primary study question will ever be definitively answered.
"The key limitation is that slow accrual led to early stopping, and this slow accrual was no doubt, an artifact, partly of the global pandemic, but also then of a change of clinical practice as a result of the CheckMate 743 study and subsequent regulatory approval and standard clinical care use," Nowak explained during her ESMO presentation.
She noted that these design modifications added complexity to trial interpretation, emphasizing that "chemotherapy alone would no longer be considered standard of care."
Future Research Directions
Despite the inconclusive primary results, Nowak highlighted that the high objective tumor response and disease control observed with durvalumab plus chemotherapy suggests potential for future investigation in the neoadjuvant setting. Correlative biomarker analyses from DREAM3R samples are ongoing and may provide insights into patient selection strategies.
The trial experience underscores broader challenges in oncology drug development. Nowak emphasized that "timely activation of randomized phase 3 trials after positive phase 2 trials is critically important to seize the window of opportunity for accrual and provide reliable answers," noting that delays in trial initiation were multifactorial.
Clinical Context and Implications
The DREAM3R results build on promising phase 2 data from the DREAM (ACTRN12616001170415) and PrE0505 (NCT02899195) trials, where durvalumab demonstrated encouraging activity in combination with pemetrexed and either cisplatin or carboplatin chemotherapy.
While the phase 3 results cannot provide definitive guidance for current clinical practice, they offer valuable insights into durvalumab's potential role in pleural mesothelioma (搜索) treatment. The observed improvements in survival outcomes and tumor response rates, particularly the statistically significant difference in objective response rates, suggest that this immunotherapy-chemotherapy combination warrants continued investigation in appropriately designed future studies.